Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Bought by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC grew its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 7.2% during the 4th quarter, Holdings Channel reports. The fund owned 19,999,999 shares of the company’s stock after purchasing an additional 1,349,999 shares during the period. Taysha Gene Therapies makes up about 0.5% of Avoro Capital Advisors LLC’s holdings, making the stock its 28th largest holding. Avoro Capital Advisors LLC owned 0.10% of Taysha Gene Therapies worth $34,600,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Cibc World Markets Corp purchased a new position in shares of Taysha Gene Therapies during the 4th quarter valued at about $28,000. E Fund Management Co. Ltd. purchased a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $31,000. AXQ Capital LP acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth approximately $39,000. Tower Research Capital LLC TRC lifted its stake in shares of Taysha Gene Therapies by 268.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 51,085 shares of the company’s stock valued at $88,000 after purchasing an additional 37,233 shares during the period. Finally, Mariner LLC grew its position in Taysha Gene Therapies by 337.5% during the fourth quarter. Mariner LLC now owns 58,342 shares of the company’s stock valued at $101,000 after buying an additional 45,006 shares during the period. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Analyst Ratings Changes

TSHA has been the topic of several recent analyst reports. Chardan Capital reissued a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Stock Up 5.1 %

NASDAQ TSHA opened at $1.24 on Monday. Taysha Gene Therapies, Inc. has a one year low of $1.05 and a one year high of $4.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The business has a fifty day moving average price of $1.54 and a 200 day moving average price of $1.81. The company has a market cap of $254.27 million, a P/E ratio of 1.97 and a beta of 0.96.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million during the quarter, compared to the consensus estimate of $2.05 million. Research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.